On Thursday, media reported that Cuba’s Center for State Control of Drugs, Equipment and Medical Devices (CECMED) is assessing the drug.

The newspapers Hoy, Diario Digital, Portada Nacional, Diario Pais RD and the digital daily Al Momento, spread the news, according to which Cuban scientists proved the safety of this product after long years of pharmaceutical, toxicological studies, of its effectiveness in animals and diseases, and the clinical trial was carried out from 2017 to 2020.

Prensa Latina reported that this project, materialized by the Center of Molecular Immunology, the Center for Research and Development of Medicines and other Cuban institutions, consisted in the develoment of a novel formulation of recombinant human erythropoietin, with similar characteristics to that produced by the brain.

According to medical literature, Alzheimer is a progressive mental disease characterized by a degeneration of brain nerve cells and a reduction of brain mass, and its basic manifestations are memory loss, time and space disorientation and intellectual and personal deterioration.

pgh/aph/mgt/ema